Skip to Main Content
Contribute Try STAT+ Today

Over the past six months, California state authorities fined more than a dozen drug makers a total of $17.5 million for failing to report price hikes as required by law, and more than half of the penalties were levied since the beginning of the year, according to data obtained by STAT.

To date, the state has only collected $4.8 million, as some fines were settled for lower amounts and other companies have yet to either make a payment or reach a settlement, according to a spokesperson for the Office of Statewide Health Planning and Development, which administers the law. Fines were assessed based on the number of days for which pricing reports were late.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.